Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29832387 | 1.00 | PTGDR (1.00) | PTGDR | |
| Hydrochloric Acid SCHEMBL4501077 | 0.99 | PTGDR (0.98) | PTGDR | |
| Phosphoric Acid SCHEMBL2470864 | 0.97 | PTGDR (0.93) | PTGDR | |
| SCHEMBL4500130 | 0.93 | PTGDR (0.87) | PTGDR | |
| SCHEMBL4142625 | 0.92 | PTGDR (0.86) | PTGDR | |
| SCHEMBL4142580 | 0.92 | PTGDR (0.85) | PTGDR | |
| SCHEMBL4489706 | 0.91 | PTGDR (0.84) | PTGDR | |
| SCHEMBL4641925 | 0.91 | PTGDR (0.83) | PTGDR | |
| SCHEMBL4489727 | 0.90 | PTGDR (1.00) | PTGDR | |
| SCHEMBL14392901 | 0.90 | PTGDR (0.81) | PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | claimed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | claimed |
| EP-2170837-B1 | PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL)-PHENYL)-2-METHYLPROPIONIC ACID | SANOFI SA (FR) | 2011-11-02 | — | — | EP | claimed |
| US-20100184979-A1 | NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID | SANOFI-AVENTIS (FR) | 2010-07-22 | — | — | US | claimed |
| EP-2170837-A2 | PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL)-PHENYL)-2-METHYLPROPIONIC ACID | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | claimed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| WO-2009006086-A2 | A NEW PROCESS FOR PREPARING 2-(3-{6-[2-(2,4-DICHLOROPHENYL)-ETHYLAMINO]-2-METHOXYPYRIMIDIN-4-YL}-PHENYL)- 2-METHYLPROPIONIC ACID | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | claimed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | claimed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | claimed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | claimed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-2653193-A1 | Method for treating macular degeneration | SANOFI (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-1948620-B1 | DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | AVENTIS PHARMA INC (US) | 2013-03-20 | — | — | EP | disclosed |
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2007047378-A2 | DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047378-A2 | DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047378-A2 | DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184979-A1 | NEW PROCESS FOR PREPARING 2-(3--PHENYL)-2-METHYLPROPRIONIC ACID | DCPS, HPD, PAH | PTGDR 494/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGDR 8/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | PTGDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.